Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Primaxin (imipenem and cilastatin, legacy) by Year
Primaxin (imipenem and cilastatin, legacy) — International sales ($M) ($M)
Merck Primaxin (imipenem and cilastatin, legacy): $211M in FY2023, down 11.3% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Primaxin | 213 | 239 | -11 | 1 | 1 | -6 | 211 | 238 | -11”
Source: Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Primaxin (imipenem and cilastatin, legacy) — International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 211 | -11.3% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2022 | Dec 31, 2022 | 238 | -7.8% | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 258 | +4.0% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 248 | -8.5% | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 271 | +5.0% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 258 | -4.4% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 270 | -7.8% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 293 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Primaxin (imipenem and cilastatin, legacy) ($M), annual FY2016–FY2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-primaxin-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.